Positioning political buying, disclosed 2026-09-25
Options put/call open interest 0.44, read 2026-11-01
Ethical does not pass the values gate
Price92.17 USD
Fair value68.93
Ethical score10.0/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-13Read Markup79.64+15.7% to today ✓Markdown gives way to Markup after a 19% rise in 11 days
2026-10-02Read Markdown67.10+37.4% to today Distribution gives way to Markdown after an 11% slide in 6 weeks
2026-08-24Read Distribution75.39+22.3% to today Markup gives way to Distribution after a 20% slide in 8 weeks
2026-07-02Read Markup94.49-2.5% to today First review on file: Markup with results news in the headlines
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Crown Castle holds its Markup at $92.17. Consolidating, no directional conviction, held for 15 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 15 days
Price at the screen
$92.17
Valuation
35.67 trailing · 30.33 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.96
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
93.81%
Below 33%
Interest-bearing debt is 93.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
1.39%
Below 49%
Money owed to the company is 1.4% of assets, under the 49% limit.
Pass
Revenue purity
0.30%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Crown Castle's business is in a permissible area, but its interest-bearing debt is about 94% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CCI's ethical verdict changes
Today CCI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our $68.93 fair value estimate.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 33.7% above the base estimate.
Where our models see it going: fair-value estimate $68.93, with a range of $68.93 to $79.27, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 30.3x forward earnings, the price already runs ahead of the business. It trades 26% above our $68.93 fair value, so you would be buying at a premium, not a discount.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CCI trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$86.58+8.2%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99.
2026-10-28Markup$80.00+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99.
2026-10-21Markup$80.00+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markup$80.00+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markup$80.00+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$80.00+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markup$80.00+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markup$80.00+0.5%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markup$79.64+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markup$79.64+0.0%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (19 analysts) rates it buy, with a mean price target of $99. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
